web analytics

Cyxone explores orphan drug designation for Rabeximod

Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company’s board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod. An orphan drug status would mean that the drug candidate obtains a strengthened position under the Orphan Drug Act, as well as prevails under special regulatory frameworks designed to endorse development and shorten time to market. This is part of the continuous work to strengthen the control position of the company’s own assets.
Kjell G. Stenberg, CEO of

Source: Cyxone explores orphan drug designation for Rabeximod

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.